HCPCS Level II code Q5117 describes an injection of trastuzumab-anns (biosimilar brand name Kanjinti) in a 10 mg unit, used for intravenous biologic therapy targeting HER2-positive malignancies; service type is a therapeutic biologic infusion/injection typically administered in an outpatient infusion center or hospital outpatient department.

For related coverage guidance, see recent payer policy updates: B-Hemolytic Streptococcus Testing, Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance Assays, Hepatitis Testing (A, B, C, D) Coverage Criteria.